Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $53M | $-3M | $-7M | $-14M | -13.7% | -1.2% | -325.2% |
| 2024 | $53M | $7M | $3M | $7M | 6.8% | -18.5% | -64.7% |
| 2023 | $65M | $13M | $8M | $-2M | 24.8% | 37.5% | -155.7% |
| 2022 | $48M | $-11M | $-15M | $-26M | 140.3% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 52.74 |
| Operating Revenue | 52.74 |
| Cost Of Revenue | 26.99 |
| Gross Profit | 25.75 |
| Operating Expense | 31.25 |
| Research And Development | 19.57 |
| Selling General And Administration | 11.68 |
| Total Expenses | 58.24 |
| Operating Income | -5.50 |
| Total Operating Income As Reported | -5.50 |
| EBITDA | -2.95 |
| Normalized EBITDA | -2.95 |
| EBIT | -4.42 |
| Interest Income | 1.08 |
| Interest Expense | 1.19 |
| Net Interest Income | -0.11 |
| Interest Income Non Operating | 1.08 |
| Interest Expense Non Operating | 1.19 |
| Net Non Operating Interest Income Expense | -0.11 |
| Pretax Income | -5.61 |
| Tax Provision | 1 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -6.60 |
| Net Income From Continuing And Discontinued Operation | -6.60 |
| Net Income From Continuing Operation Net Minority Interest | -6.60 |
| Net Income | -6.60 |
| Net Income Common Stockholders | -6.60 |
| Net Income Including Noncontrolling Interests | -6.60 |
| Normalized Income | -6.60 |
| Diluted NI Availto Com Stockholders | -6.60 |
| Basic Average Shares | 78.55 |
| Diluted Average Shares | 78.55 |
| Reconciled Depreciation | 1.46 |
| Reconciled Cost Of Revenue | 26.99 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Protalix BioTherapeutics, Inc.this co. | PLX | $162M | - | 3.36 | -13.7% | - |
| Quanterix Corporation | QTRX | $179M | -1.67 | 0.61 | -36.2% | -2.05 |
| Journey Medical Corporation | DERM | $171M | -14.98 | 5.38 | -35.9% | -51.87 |
| Inogen, Inc. | INGN | $171M | -7.51 | 0.89 | -11.8% | -8.86 |
| ADC Therapeutics SA | ADCT | $168M |
| - |
| - |
| - |
| - |
| - |
| - |
| -1.18 |
| -0.90 |
| 76.7% |
| -0.27 |
| Korro Bio, Inc. | KRRO | $161M | -1.38 | 3.13 | -228.0% | -2.20 |
| CVRx, Inc. | CVRX | $156M | - | 3.97 | -135.6% | - |
| Nano-X Imaging Ltd. | NNOX | $144M | -1.92 | 1.03 | -53.7% | -2.10 |
| Health Catalyst, Inc. | HCAT | $143M | -0.81 | 0.58 | -72.4% | -2.57 |
| Peer Median | - | -1.67 | 0.96 | -45.0% | -2.20 | |